Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Bill & Melinda Gates Foundation, European Research Council.

Who Took Part

By PubMed's age tags, the people studied were young children, children, teenagers, young adults, adults and middle-aged adults.

The researchers enrolled male participants aged 5-50 years with asymptomatic P falciparum malaria.

Laboratory staff, investigators, and insectary technicians were masked to the treatment group and gametocyte density of study participants.

How the Study Was Run

In design terms this was a randomized and single-blind study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Only one side, usually the participants, was kept unaware of whether Methylene blue (non-peptide stack partner) was given.

This was a phase 2, single-blind, randomised controlled trial done at the Clinical Research Centre of the Malaria Research and Training Centre (MRTC) of the University of Bamako (Bamako, Mali).

This study is registered with ClinicalTrials.gov, number NCT02831023.

What Was Measured

Topics PubMed links to this paper include Amodiaquine, Artemisinins, Drug Combinations, Malaria, Falciparum, Mali, Methylene Blue and Plasmodium falciparum.

What This Means in Plain Language

The paper is a randomized and single-blind study of Methylene blue (non-peptide stack partner).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (The Lancet. Infectious diseases), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.